Journal article
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus
Abstract
The effects of pravastatin (pravachol) compared with gemfibrozil on cholesterol-rich and trigylceride-rich lipoproteins were evaluated in this multi-centered trial. Following an 8-12 week prerandomization phase, 136 patients with NIDDM and hypercholesterolemia were randomized to receive either pravastatin 40 mg or gemfibrozil 1200 mg daily for 16 weeks. The reduction of total cholesterol (TC), betaquant LDL and LDL cholesterol (LDL-C) was …
Authors
Schweitzer M; Tessier D; Vlahos WD; Leiter L; Collet JP; McQueen MJ; Harvey L; Alaupovic P
Journal
Atherosclerosis, Vol. 162, No. 1, pp. 201–210
Publisher
Elsevier
Publication Date
May 2002
DOI
10.1016/s0021-9150(01)00700-6
ISSN
0021-9150
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedApolipoproteinsCholesterol, LDLCholesterol, VLDLDiabetes Mellitus, Type 2Double-Blind MethodDrug EvaluationFemaleFollow-Up StudiesGemfibrozilHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemiasHypolipidemic AgentsLipoproteinsMaleMiddle AgedPatient CompliancePhenotypePravastatinTreatment OutcomeTriglycerides